Biohaven Targets Muscle Preservation

Why Does Muscle Preservation Matter in Obesity Treatment?

The widespread adoption of GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound) has transformed obesity medicine. However, clinical observations suggest that a substantial portion of total weight lost — by some estimates up to 40 percent — comes from lean tissue rather than fat. For younger adults with obesity, this may have limited functional consequences, but for older patients, athletes, and those with existing sarcopenia, the loss of skeletal muscle can compromise strength, metabolic health, and physical independence.

This concern has spurred a new wave of pharmaceutical research focused on preserving or building muscle mass during weight loss. Several companies, including Biohaven Pharmaceutical, are advancing molecules that target the myostatin and activin signaling pathways — biological brakes on muscle growth. By inhibiting these pathways, the drugs aim to allow weight loss to occur while protecting or even enhancing lean body mass.

How Do Myostatin Inhibitors Work?

Myostatin, also known as growth differentiation factor 8 (GDF-8), is a member of the transforming growth factor-beta superfamily and acts as a powerful negative regulator of skeletal muscle mass. Animals and rare humans with myostatin gene mutations exhibit dramatically increased muscle bulk. Pharmacological inhibition of myostatin and the related activin pathway has been studied for decades in conditions ranging from muscular dystrophy to cancer cachexia, with mixed clinical results.

The current generation of muscle-preserving candidates aims to complement, rather than replace, GLP-1 therapies. The therapeutic vision is a combination regimen in which a GLP-1 drug drives caloric restriction and fat loss while a myostatin or activin inhibitor preserves the metabolically active muscle tissue. Whether such combinations deliver meaningful improvements in body composition, physical function, and long-term cardiometabolic outcomes will depend on results from ongoing and planned phase 2 and phase 3 trials.

What Are the Clinical and Commercial Stakes?

Industry analysts project the obesity therapeutics market could surpass $100 billion within a decade, driven by demand from an estimated 890 million adults living with obesity worldwide according to the World Health Organization. As Eli Lilly, Novo Nordisk, and other established players battle for dominance with incrementally improved GLP-1 and dual or triple incretin agonists, smaller biotechs are seeking differentiation through complementary mechanisms.

Beyond commercial considerations, the clinical question is significant. Major medical bodies, including the American College of Cardiology and obesity specialty societies, have called for more robust data on body composition outcomes, not just total weight on the scale. If muscle-preserving agents can demonstrate improved physical function, reduced frailty risk, and durable metabolic benefits, they could reshape treatment guidelines for older adults and patients at risk of sarcopenic obesity.